SAT0314 IMPLEMENTATION OF AN ASSESSMENT CHECKLIST FOR PATIENTS WITH SPONDYLOARTHRITIS IN DAILY PRACTICE

Background Nowadays, despite international and national guidelines on the evaluation and management of spondyloarthritis (SpA), several studies have depicted a sub-optimal assessment of these diseases. Objectives To analyze the feasibility and changes in the collection of clinical measures after the implementation in daily practice of a checklist designed for an optimal evaluation and monitoring of patients with SpA, including psoriatic arthritis (PsA). Methods An observational prospective study was performed. The feasibility of the assessment checklist (paper/on-line format) for patients with SpA was tested (time to complete the checklist, simplicity, amenity clarity, usefulness). Through a medical files review, changes in the number of the checklist variables collected were analyzed previous to the implementation of the checklist and 6 months later. A descriptive and bivariate analysis was performed. Results A total 6 hospitals and 11 rheumatologists participated. The median time to checklist completion was 15 (12-20) minutes, and the mean scores for the rest of variables of the feasibility test were in general positives, 6.9±1.1 (simplicity) and 6.9±0.8 (amenity), to 7.5±1.2 (clarity) and 7.5±1.4 (usefulness). A total of 83 and 68 medical files pre-implementation and post-implementation were reviewed respectively. Patient’s features were similar. Mean age at diagnosis was 42.3±1.6 and 40.3±1.3 years respectively. In both study samples around a half of patients were men, and axial SpA and PsA were equally distributed as well (40.2% and 44.8% pre- and post-implementation (47.6% and 47.8%). We observed a significant increase in the collection of many of the checklist variables after the implementation. The record of BASDAI increased from 46.2% to 73.1% (p=0.001), physical activity from 48.2% to 88.2% (p Conclusion The implementation of an assessment checklist in daily practice is feasible and improve the assessment of SpA patients. Acknowledgement To Maria Jesus Garcia de Yebenes for her methodological support. Disclosure of Interests RAQUEL ALMODOVAR: None declared, Beatriz Joven-Ibanez Speakers bureau: Celgene, Novartis, MSD, Pfizer, AbbVie, and Janssen, Esther Rodriguez Almaraz: None declared, Sheila Melchor: None declared, Elena Rabadan: None declared, Virginia Villaverde: None declared, Ma Teresa Navio: None declared, Laura Cebrian: None declared, Leticia Lojo: None declared, Alejandro Prada-Ojeda: None declared, Laura Gonzalez: None declared, Alvaro Garcia Martos: None declared, Victoria Navarro-Compan: None declared, Estibaliz Loza Grant/research support from: Roche, MSD, Pfizer, Abbvie, BMS, UCB, Actelion, Celgene, Grunenthal and Sanofi, Pedro Zarco-Montejo: None declared